首页> 外文会议>Reporters, markers, dyes, nanoparticles, and molecular probes for biomedical applications V >Suppressing inflammation from inside out with novel NIR visible perfluorocarbon nanotheranostics
【24h】

Suppressing inflammation from inside out with novel NIR visible perfluorocarbon nanotheranostics

机译:通过新型近红外可见全氟化碳纳米热疗从内到外抑制炎症

获取原文
获取原文并翻译 | 示例

摘要

Highly innovative multimodal perfluorocarbon (PFC) nanoemulsions are presented. They serve simultaneously as dual-mode imaging reagents (NIR and ~(19)F MRI), and drug delivery vehicles for water insoluble cyclooxgenase-2 (COX-2) inhibitors. These features qualify them as theranostic. Cancer progression and metastasis are highly influenced by tumor microenvironment and inflammation. Infiltration of primary tumors with inflammation-promoting cells (e.g. macrophages) is a negative prognostic factor for cancer patient survival. We postulate that the suppression of COX-2 enzyme in macrophages by theranostic PFC nanoemulsions will result in changes in macrophage levels of accumulation in tumors and/or their phenotype, which can suppress tumor-promoting activity. The presented theranostic nanoemulsions are designed to label immune cells such as macrophages, and deliver celecoxib, a COX-2 inhibitor. The designed theranostic incorporates two fluorescent reporters: a near-infrared (NIR) fluorescent dye for improved optical in vivo imaging, and a distinct fluorescent dye for histological analysis of excised tissues. A high content of PFC in the theranostic allows ~(19)F MRI to quantitatively assess the distribution of the injected nanomedicine in the peritumoral area, and measure tumor-associated inflammation, while ~1H MRI provides anatomical context. NIR imaging is used as a complementary in vivo technique to assess biodistribution of the theranostic. We report preparation and characterization of the nanoemulsions' colloidal and optical stability, in vitro toxicity, and imaging capabilities. This theranostic offers flexibility for in vitro and in vivo inflammation imaging and histological analysis using three different imaging functionalities (fluorescence, NIR and ~(19)F MRI), advancing the monitoring and modulating of tumor-infiltrating immune cells in vivo.
机译:介绍了高度创新的多峰全氟化碳(PFC)纳米乳液。它们同时用作双模式成像试剂(NIR和〜(19)F MRI)以及水不溶性环氧合酶2(COX-2)抑制剂的药物递送载体。这些功能使它们成为诊断专家。肿瘤的微环境和炎症高度影响着癌症的进展和转移。炎症促进细胞(例如巨噬细胞)浸润原发性肿瘤是癌症患者生存的不良预后因素。我们推测,治疗性PFC纳米乳剂抑制巨噬细胞中COX-2酶会导致巨噬细胞在肿瘤中的蓄积水平和/或其表型发生变化,从而可以抑制促肿瘤活性。提出的治疗性纳米乳剂旨在标记免疫细胞(例如巨噬细胞),并递送塞来昔布(一种COX-2抑制剂)。设计的治疗诊断法包含两种荧光报告分子:一种用于改善体内光学成像的近红外(NIR)荧光染料,一种用于切除组织的组织学分析的独特荧光染料。术中PFC含量高,使得〜(19)F MRI能够定量评估肿瘤周围区域注射的纳米药物的分布,并测量与肿瘤相关的炎症,而〜1H MRI提供了解剖学背景。 NIR成像被用作体内的补充技术,以评估治疗诊断的生物分布。我们报告纳米乳液的胶体和光学稳定性,体外毒性和成像功能的制备和表征。该治疗诊断法使用三种不同的成像功能(荧光,NIR和〜(19)F MRI)为体外和体内炎症成像和组织学分析提供了灵活性,从而促进了体内肿瘤浸润免疫细胞的监测和调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号